Elevation Oncology Acquired After Ending Partnership with CSPCCSPCElevation Oncology has been acquired by Concentra Biosciences after halting its Claudin18.2 ADC program with CSPC. The deal includes a $22M valuation and future rights tied to EO-1022, its sole remaining HER3-targeted ADC candidate.
EN
Agricultural News
Food News
Industrial News
Cosmetic News
Pharmaceutical News
Science News
